Singapore eDevelopment subsidiary Global BioLife's 3F Antimicrobial Fragrance shows Efficacy against Tuberculosis
SINGAPORE, Jan, 28 2019 - (ACN Newswire) - SGX-listed Singapore eDevelopment Ltd (SeD) is pleased to announce that its U.S. biomedical subsidiary Global BioLife Inc. has developed 3F Antimicrobial Fragrance, which shows efficacy against tuberculosis. Tuberculosis is the leading cause of deaths from a single infectious agent, infecting about one quarter of the world's population.
The fragrance was shown to inhibit Mycobacterium tuberculosis (MTB), the causative bacterial agent of tuberculosis. The experiments were performed at ATCC, as a custom service within its High Containment Laboratory under BioSafety Level 3 conditions. ATCC is a premier global biological materials and information resource and standards organization, with proven expertise in the safe handling and experimentation on dangerous pathogens such as MTB.
Mr. Daryl Thompson, Global BioLife's Director of Scientific Initiatives, and a Nobel Prize nominee in 2015 and 2016 for his research on pandemic technology, leads research on the 3F Antimicrobial Fragrance. "3F works by taking advantage and exploiting the bacterial or viral sophisticated communication system called quorum sensing.
"In essence, we can utilise quorum sensing to instruct the bacterial or viral agent to shut down or stop replication.The 3F project was designed to provide a solution for open environment defence strategies, to prevent or suppress the transmission of aerosoled viral and bacterial particles that cause the spread of influenza, MRSA and tuberculosis in congested areas. The process has been demonstrated to be very effective."
"As a leading developer of authenticated cells lines and microorganisms, ATCC was honored to provide Global BioLife with custom susceptibility testing to determine if their product was able to kill MTB," said Dr. Manzour Hazbon, ATCC Senior Scientist. "This fragrance is very effective even in low concentrations, and an excellent candidate to treat tuberculosis, particularly important as there are few antibiotics effective in treating antibiotic-resistant tuberculosis cases."
Mr Chan Heng Fai, Executive Chairman of SeD said, "We are excited about the potential of this breakthrough in 3F Antimicrobial, and Global GioLife will step up in its continued efforts to provide cutting edge research into real solutions for global healthcare problems."
Dr. Roscoe M. Moore Jr, former Senior Assistant Surgeon General of the U.S. and highly-regarded public health expert who serves as Senior Scientific Adviser to Global BioLife, says "I'm excited about 3F's potential to address a global epidemic by providing safe and versatile protection layers."
"Tuberculosis is a global priority and Global BioLife's solution will help save lives on a global scale." Dr. Moore also served as Epidemic Intelligence Service Officer with the U.S. Center for Disease Control and Prevention, and as Chief Epidemiologist with the Center for Devices and Radiological Health in the U.S. Food and Drug Administration.
Also advising Global BioLife is Lieutenant Colonel William H. Lyerly Jr., a former Scientific Professional (ST) with the U.S. Government Civil Service and retired U.S. Army Medical Service Corps Officer with an extensive medical background including disaster relief, development, biodefense, interagency and civilmilitary cooperation and teaching.
"As TB's person-to-person spread requires only a small number of bacteria and transmission is most rapid in confined spaces, 3F efficacy is especially promising. And as multidrug-resistant TB continues a global health crisis and security threat, 3F's environmental intervention represents an effective and less-costly TB control strategy in high-transmission areas worldwide."
Global Biolife has partnered with Destum Inc to license its 3F technology to global manufacturers and distributers. 3F Mosquito, unlike repellents such as DEET, was developed as an additive to laundry detergents and lotions for layered protection against mosquitos. 3F Antimicrobial was developed as an additive for sprays, filters and dispersal systems in hospitals, transit and open areas to protect against bacteria and viruses.
Global BioLife (GBLI) is 70%-held by Global BioMedical, owned by Singapore BioMedical Ltd, owned by Singapore eDevelopment. 20% held by Global Research & Discovery Group LLC (GRDGS) and 10% by ASX-listed Holista CollTech. Tapping GRDGS & Holista expertise, GBLI pledges a concerted effort at prevention and treatment of neurological, oncology and immuno-related diseases. See www.globalbiolife.com.
GRDGS LLC is an advanced research team formed in Florida by natural products discovery drug research scientist, Daryl Thompson. For more information, visit www.globalrdg.com.
Singapore eDevelopment (SGX:V40), www.SeD.com.sg or [email protected].
Source: Singapore eDevelopment Ltd
Sectors: BioTech, HealthCare, Cosmetics/Spec.Chem
Copyright ©2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
More Latest Release >>
Toyota Provides Diverse Mobility for Tokyo 2020, including a Full Line-up of Electrified Vehicles
Aug 23, 2019 16:58 JST
NEC Receives Order for Intelligent Transportation System in Makkah, Saudi Arabia
Aug 23, 2019 11:42 JST
MHI to Exhibit at the Japan-Africa Business Expo during TICAD7
Aug 22, 2019 14:20 JST
Fujitsu and Qualcomm Complete 5G Data Calls in Sub-6 GHz and mmWave Spectrum Bands
Aug 22, 2019 11:13 JST
NEC: Industrial Internet Consortium Approves Testbed of Negotiation Automation Platform for coordinating interests among AI systems
Aug 21, 2019 11:24 JST
NEC to Install More than 20MW of Municipal Energy Storage Projects in New England
Aug 21, 2019 11:01 JST
Fernando Alonso Keeps an Eye on Dakar with TOYOTA GAZOO Racing
Aug 20, 2019 17:06 JST
MHIEC Receives Order to Refurbish the Hiroshima Naka Waste to Energy Plant
Aug 20, 2019 11:10 JST
New Combustor Center for Manufacturing Aero Engine Parts to be Established within MHI's Nagasaki Shipyard & Machinery Works
Aug 19, 2019 12:49 JST
Toyota Yaris WRC Ready to Master the Varied Roads of Germany
Aug 16, 2019 20:13 JST
Fujitsu Develops AI Disaster Mitigation Technology to Predict River Flooding with Limited Data
Aug 16, 2019 14:15 JST
ULVAC Launches Revolutionary PZT Piezoelectric Thin-film Process Technology and HVM Solution for MEMS Sensors/Actuators
Aug 16, 2019 14:00 JST
Honda Announces Changes in Production Operations in Argentina
Aug 14, 2019 09:04 JST
The HondaJet is the Most Delivered Aircraft in its Class for the First Half of 2019
Aug 13, 2019 10:47 JST
Notice of Signing Basic Agreements for Airport Operation of the Seven Airports in Hokkaido
Aug 09, 2019 17:05 JST
MHI Developing the QoEn Index for Energy Infrastructure to Support the Sustainable Growth of Society
Aug 09, 2019 14:04 JST
Fujitsu Initiates Year-Round Recruitment
Aug 09, 2019 11:27 JST
Mitsubishi Motors to Introduce its Customers to a New Energy Plan by MC Retail Energy
Aug 08, 2019 19:20 JST
Fujitsu RunMyProcess Joins Google Cloud Partner Program
Aug 08, 2019 09:00 JST
SDK Revises 2019 Consolidated Performance Forecast
Aug 07, 2019 16:05 JST